ArticleFamilial cancer2019

Should unaffected female BRCA2 pathogenic variant carriers be told there is little or no advantage from risk reducing mastectomy?

D Gareth Evans et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.